Hypothyroidism and Zepbound or Ozempic: Levothyroxine, TSH, and Weight

The short answer

Yes, most women with hypothyroidism or Hashimoto's can take Zepbound, Ozempic or Wegovy. The thyroid boxed warning is about medullary thyroid cancer and an inherited syndrome called MEN 2, not an underactive thyroid. What does change is practical: when you take levothyroxine, and how soon your TSH gets rechecked as weight comes off.

If you have been on levothyroxine for years and the warning on the box made your stomach drop, this page is for you.

Why hypothyroid women ask this first

Weight is one of the most common complaints among people treated for an underactive thyroid. In a survey of 12,146 people with hypothyroidism, posted on the American Thyroid Association's website, overall satisfaction with treatment had a median of 5 out of 10, and respondents on levothyroxine were among the most likely to report problems with weight management, fatigue and mood¹². So it is no surprise that women on a thyroid pill are often the first to ask about a GLP-1, and the most worried when they see the word "thyroid" printed in a black box.

The boxed warning, explained in one table

The warning on every GLP-1 label comes from rodents. Semaglutide and tirzepatide caused thyroid C-cell tumors in rats and mice, and it is unknown whether they do so in people. The drugs are contraindicated if you or a family member has had medullary thyroid carcinoma (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)^1,2.

C-cells are a small, separate population of cells in the thyroid that make calcitonin. They are not the cells that make thyroid hormone, and they are not what goes wrong in hypothyroidism or Hashimoto's.

What about thyroid cancer in people? The human data are mixed but reassuring on balance. A French database study found GLP-1 use for one to three years was linked to more thyroid cancer, including medullary⁷. A larger Scandinavian cohort of more than 145,000 people starting GLP-1 drugs found no meaningful increase over an average of 3.9 years, with a hazard ratio of 0.93⁸. If you have a thyroid nodule being watched, mention the GLP-1 at your next scan.

Levothyroxine timing with the shot vs the pill

The weekly injections. Zepbound and the semaglutide pens slow how fast your stomach empties, and the Zepbound label notes this effect is strongest after the first dose and fades with time¹. Labels ask clinicians to monitor oral drugs that need a precise level, and levothyroxine is one: its own label calls it a narrow-therapeutic-index drug⁵. Keep taking it the usual way, on an empty stomach 30 to 60 minutes before breakfast, at least four hours apart from drugs that block absorption⁵.

The daily semaglutide tablets. This is the bigger interaction. In a drug-interaction study, taking levothyroxine with oral semaglutide raised total thyroxine exposure by 33%^3,4. And both pills want the same slot: semaglutide tablets go on an empty stomach in the morning with up to four ounces of water, with a 30-minute wait before any food, drink or other medicine³.

So two pills compete for one empty-stomach morning. Do not improvise a new routine on your own. Ask your prescriber how to separate them, then keep that routine identical every day, because consistency is what makes a TSH result mean something. If you are choosing between a tablet and an injection, the levothyroxine question is a fair reason to lean toward the shot.

Why your dose may need to drop as weight drops

Levothyroxine is dosed partly by body weight: full replacement is about 1.6 micrograms per kilogram per day⁵. Lose 15% or 20% of your weight, and the dose that was right at your old weight can become too much. Slower stomach emptying can also change how much of each pill you absorb.

The label's rule for adults is to recheck TSH six to eight weeks after any dose change, and every six to twelve months once stable, or sooner when your health changes⁵. Large weight loss counts as a change.

In practice, the recheck often does not happen. A 2026 study of more than 5,000 older Medicare patients on stable levothyroxine found those starting a GLP-1 waited an average of about 130 days for a TSH test, no sooner than people starting a different diabetes drug, which the authors called a missed opportunity⁹. A 2026 case report shows the cost of the miss: a 52-year-old woman without a thyroid lost 48 pounds on tirzepatide over six months on an unchanged levothyroxine dose, and arrived with a racing heart, dizziness and confusion from too much thyroid hormone¹⁰.

What to ask for:

• A TSH before you start, so you have a baseline.
• A recheck once you have lost a meaningful amount of weight, rather than waiting for the yearly check.
• A recheck if you feel shaky, wired, sleepless or have a racing heart. Those can be signs of too much levothyroxine, not just the drug.
• A recheck if you switch between the GLP-1 tablet and the injection.

Can hypothyroidism blunt GLP-1 weight loss?

Not if it is well treated, on the evidence so far. In a 2025 study, 53 people with treated hypothyroidism who took liraglutide lost 10.8% of their weight on average, compared with 8.9% in matched people without thyroid disease, a difference that was not significant. Body composition changes were similar, and TSH within the normal range did not predict results¹¹. That was an older GLP-1, one center, and a retrospective design, so treat it as reassurance rather than proof.

What can blunt results is an under-replaced thyroid. If your TSH is high, fixing that comes first. And thyroid hormone itself is not a weight-loss tool: the levothyroxine label carries a boxed warning against using it for weight loss, because doses large enough to move weight can be dangerous⁵. The American Thyroid Association's guideline keeps levothyroxine as the standard of care for hypothyroidism⁶.

Pregnancy, postpartum and the thyroid pill

Two thyroid facts collide with motherhood. Pregnancy often raises the levothyroxine dose you need, and after delivery the label says to return to the pre-pregnancy dose and recheck TSH four to eight weeks postpartum⁵. GLP-1 drugs, meanwhile, are stopped in pregnancy, and semaglutide two months before a planned one. If you are postpartum and thinking about starting a GLP-1, let the thyroid settle first. Our guide to GLP-1 timing after birth and while breastfeeding covers the rest of that window.

For more on what to bring to your first appointment, read what to tell your OB before starting a GLP-1. Some programs, such as Allara Health, list Hashimoto's among the conditions they treat alongside weight, which helps when your thyroid and your GLP-1 are managed in one place.